TITAN Phase 3 trial

February 16, 2021February 16, 2021

Erleada-ADT Combo Found to Prolong Survival, Delay Cancer Worsening

News

When given in combination with androgen deprivation therapy or ADT, Erleada (apalutamide) significantly prolonged the lives of men with metastatic hormone-sensitive prostate cancer (mHSPC) — without compromising their quality of ... Read more

January 29, 2020January 30, 2020

Erleada Approved in Europe to Treat Metastatic Hormone-sensitive Prostate Cancer

News

The European Commission (EC) has agreed to extend the use of Janssen’s Erleada (apalutamide) to treat men whose metastatic prostate cancer still responds to androgen deprivation therapy (ADT), a condition known ... Read more

January 6, 2020January 30, 2020

EMA Committee Favors Extending Use of Erleada for Metastatic Castration-sensitive Prostate Cancer

News

The Committee for Medicinal Products for Human Use recommends extending the use of Janssen’s Erleada (apalutamide), in combination with androgen deprivation therapy (ADT), to treat men with metastatic hormone-sensitive prostate cancer ... Read more

October 17, 2019

Erleada-ADT Combo Increases Survival of mCSPC Patients Without Affecting Quality of Life, Phase 3 Trial Shows

News

Adding Erleada (apalutamide) to standard androgen deprivation therapy (ADT) increases the survival and delays disease progression in men with metastatic castration-sensitive prostate cancer (mCSPC) — and does so without compromising ... Read more

September 19, 2019

FDA Approves Erleada to Treat Metastatic Castration-sensitive Prostate Cancer

News

The U.S. Food and Drug Administration (FDA) has approved Erleada (apalutamide) for the treatment of men with metastatic castration-sensitive prostate cancer (mCSPC), or those whose cancer still responds to androgen deprivation ... Read more

June 5, 2019

Trial Shows Erleada Can Prolong Metastatic Castration-sensitive PC Patients’ Lives

News

Adding Erleada (apalutamide), Janssen‘s next-generation androgen receptor inhibitor, to androgen deprivation therapy (ADT) can prolong life and extend the time without disease worsening in men with metastatic castration-sensitive prostate cancer, ... Read more

May 6, 2019

Janssen Seeks Expanded FDA Approval of Erleada to Treat Metastatic Castration-sensitive Prostate Cancer

News

Janssen has submitted an application with the U.S. Food and Drug Administration (FDA) seeking the approval of its androgen receptor inhibitor Erleada (apalutamide) for patients with metastatic castration-sensitive prostate cancer (CSPC). ... Read more

February 4, 2019

Erleada Improves Survival in Metastatic Castration-Sensitive Prostate Cancer, Phase 3 Trial Finds

News

Adding Janssen‘s androgen receptor inhibitor Erleada (apalutamide) to first-line androgen deprivation therapy (ADT) significantly extended survival and delayed disease progression or death in metastatic castration-sensitive prostate cancer patients included in a Phase 3 ... Read more